MannKind Corporation is part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Michael E. Castagna. MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.

Previous Intraday Performance:

The MNKD shares had a previous change of -2.44% which opened at 1.24 and closed at 1.20. It moved to an intraday high of 1.26 and a low of 1.20.

SeekingAlpha:  MannKind: Brazil Approval, Scripts, Cash

Historical Performance:

Over the last five trading days, MNKD shares returned 0.00% and in the past 30 trading days it returned -25.00%. Over three months, it changed -30.23%. In one year it has changed -38.46% and within that year its

52 week high was 3.04 and its 52 week low was 0.94. MNKD stock is 27.66% above its 52 week low.

Our calculations result in a 200 day moving average of 1.59 and a 50 day moving average of 1.52. Right now, MNKD stock is trading -24.36% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  MannKind: Brazil Approval, Scripts, Cash


The company has a market cap of $225.3m with 187.8m shares outstanding and a float of 183.3m shares. Trading volume was 1,782,685 shares and has experienced an average volume of 2,046,301 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for MannKind Corporation was -0.61 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.08.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-07-2019: -0.08
4thQtr 2018Reported 02-26-2019: -0.04
3rdQtr 2018Reported 11-01-2018: -0.16
2ndQtr 2018Reported 08-02-2018: -0.16
1stQtr 2018Reported 05-09-2018: -0.25

Base on our calculations, the intrinsic value per share is 0.59, which means it might be overvalued by -103.46%.

The growth of the EPS is critical in understanding the current valuation of MannKind Corporation; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 126.40% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 46.60% of institutional ownership.

The beta was calculated to be 2.48.

SeekingAlpha:  County Bancorp beats by $0.02, beats on revenue

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -90.86%, price-to-sales is 5.52 and.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 2  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here